RE:RE:Adios ViaCyteMakes you wonder what SVA is doing wrong or what Spill did to piss off Vertex enough for them to buy everyone except them.
My guess is Vertex is looking at ViaCyte's immuno tech & partnership with CRISPR. ViaCyte's human clinical trial has started in Feb 2022 using the gene edited stem cells that don't need immuno suppression. So everyone who thinks that Sernova is way further along need to think again. We are still experimenting with conformal coating in lab rats.
The only potential good news here is the fact that Vertex only paid 320 mil. That tells me the results are probably not going to be great. Could also just mean that Vertex was almost out of cash again and couldn't raise anything in today's capital markets and took what they could or face shutting down.
Had they offered Sernova 2 billion, it would have been a done deal and they would have been way further ahead as soon as they put Phil in a lab coat and fire the rest of management. Maybe this news will motivate other big pharma to scoop up Sernova at it's current discount price.